1190results about How to "Improve expression level" patented technology

The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provide methods of identifying inhibitors of tumorigenesis.

The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.

A method for delivering a polynucleotide to cardiac tissue, including substantially isolating the coronary venous circulation from systemic circulation, and introducing a polynucleotide into the isolated coronary venous circulation to effect localized transfection of cardiac tissue. The polynucleotide advantageously produces a therapeutic effect, such as increasing or decreasing the expression level of a protein in the cardiac tissue.

Methods of shuffling DNA to obtain recombinant herbicide tolerance nucleic acids encoding proteins having new or improved herbicide tolerance activities, libraries of shuffled herbicide tolerance nucleic acids, transgenic plants and DNA shuffling mixtures are provided.

The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.

Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.

The present invention provide methods of imparting stress tolerance, characterized in that an expression amount of at least one stress defense gene is increased compared with a non-transformant by transforming the plant with an exogenous spermidine synthase (SPDS) gene, an exogenous S-adenosylmethionine decarboxylase (SAMDC) gene, an exogenous arginine decarboxylase (ADC) gene, an ornithine decarboxylase (ODC) gene and/or a spermine synthase (SPMS) gene under the control of a promoter capable of functioning in the plant.

The present invention provides an agent which is effective to a patient who is administered by an agent comprising anti-CD20 antibody as an active ingredient.

The invention relates to an anti-human transferrin receptor human antibody and the application, which pertains to the field of molecular biology. The anti-human transferrin receptor human antibody has a single-chain antibody (scFv) amino acid sequence which is shown in a sequence table SEQ ID No.1. The anti-human transferrin receptor human antibody and the application have the advantages that: the human antibody solves the problem of immunogenicity of the target antibody, thus allowing the human antibody to carry out the long-term repeated drug administrations in the human body; the method for screening a genetic engineering antibody in a large-capacity antibody library which is adopted by the invention is easier than the monoclonal antibody preparation, the large-scale production is easy, the molecule of the antibody is small, and the antibody can enter tissues deeply, thus having obvious advantages. A pET-22b (plus) vector which is adopted by the invention contains a stronger T7 promoter, which can ensure the higher expression level of the target antibody. The induced expression conditions after the optimization can ensure that the antibody is expressed in a soluble form and the activity of protein is higher. The 3' end of the pET-22b (plus) vector is provided with six His(histidine) labels, which can easily use the Ni-NTA agarose to carry out affinity chromatography and purification.

A method of amplifying a template DNA molecule comprising incubating the template DNA molecule in a reaction mixture comprising a DNA polymerase and at least one accessory protein at a constant temperature to produce amplified product, wherein production of amplified product does not require exogenously-added oligonucleotide primers and the template DNA molecule does not have have terminal protein covalently bound to either 5′ end.

Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.

The present invention provides methods comprising both genetic and chemical means for the production of hepatocytes from a variety of cell sources, particularly pluripotent stem cells.